{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:06:30Z","timestamp":1789070790099,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004541","name":"MHRD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.thromres.2024.04.031","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T01:22:43Z","timestamp":1714699363000},"page":"151-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B"],"prefix":"10.1016","volume":"238","author":[{"given":"Pratiksha","family":"Sarangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramkumar","family":"Sambasivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivaprakash","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhara R.","family":"Jayandharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.thromres.2024.04.031_bb0005","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-7-24","article-title":"Past, present and future of hemophilia: a narrative review","volume":"7","author":"Franchini","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.031_bb0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/hae.14012","article-title":"The World Federation of Hemophilia annual global survey 1999\u20132018","volume":"26","author":"Stonebraker","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2024.04.031_bb0020","first-page":"1","article-title":"Hemophilia: genetics, diagnosis and treatment","volume":"1","author":"Jayandharan","year":"2011","journal-title":"Genet. Syndr. Gene. Ther."},{"issue":"11","key":"10.1016\/j.thromres.2024.04.031_bb0025","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0030","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1055\/s-0031-1300953","article-title":"Role of molecular genetics in hemophilia: from diagnosis to therapy","volume":"38","author":"Jayandharan","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2008-1066024","article-title":"The phenotypic heterogeneity of severe hemophilia","volume":"34","author":"Jayandharan","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.031_bb0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.04.031_bb0050","first-page":"864","article-title":"Individualizing factor replacement therapy in severe hemophilia","author":"Carcao","year":"2015","journal-title":"Semin. Thromb.Hemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2004.05110.x","article-title":"Dose and response in haemophilia\u2013optimization of factor replacement therapy","volume":"127","author":"Srivastava","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.031_bb0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1542\/pir.34.7.289","article-title":"Hemophilia: in review","volume":"34","author":"Zimmerman","year":"2013","journal-title":"Pediatr. Rev."},{"issue":"12","key":"10.1016\/j.thromres.2024.04.031_bb0065","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","volume":"16","author":"Shapiro","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"23","key":"10.1016\/j.thromres.2024.04.031_bb0070","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.031_bb0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2042098611415566","article-title":"Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes","volume":"2","author":"Shapiro","year":"2011","journal-title":"Ther. Adv. Drug. Saf."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.031_bb0080","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-0037-1612626","article-title":"Inhibitors in hemophilia: treatment challenges and novel options","volume":"44","author":"Barg","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2024.04.031_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0037-1963(01)90140-4","article-title":"The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis","volume":"38","author":"Hoffman","year":"2001","journal-title":"Semin. Hematol."},{"issue":"20","key":"10.1016\/j.thromres.2024.04.031_bb0090","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1182\/blood-2014-05-576892","article-title":"In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia","volume":"124","author":"Augustsson","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-2006-939557","article-title":"Mechanism of action of factor VIIa in the treatment of coagulopathies","volume":"32","author":"Hedner","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2024.04.031_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.seminhematol.2003.11.008","article-title":"Dosing with recombinant factor VIIa based on current evidence","volume":"41","author":"Hedner","year":"2004","journal-title":"Semin. Hematol."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.031_bb0105","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","article-title":"Gene therapy for hemophilia","volume":"25","author":"Nienhuis","year":"2017","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.031_bb0110","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1046\/j.1538-7836.2003.00262.x","article-title":"Hemophilia: treatment options in the twenty-first century","volume":"1","author":"Mannucci","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.thromres.2024.04.031_bb0115","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/hum.2017.167","article-title":"Advances in gene therapy for hemophilia","volume":"28","author":"Nathwani","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"21","key":"10.1016\/j.thromres.2024.04.031_bb0120","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv."},{"issue":"23","key":"10.1016\/j.thromres.2024.04.031_bb0125","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.thromres.2024.04.031_bb0130","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.thromres.2024.04.031_bb0135","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector\u2013mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.thromres.2024.04.031_bb0140","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1182\/bloodadvances.2017009878","article-title":"Hemophilia gene therapy comes of age","volume":"1","author":"George","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2024.04.031_bb0145","first-page":"3331","article-title":"101HEMB01 is a phase 1\/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with moderate\/severe hemophilia B that demonstrated meaningful but transient expression of human factor IX (hFIX)","volume":"130","author":"Pipe","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.031_bb0150","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1172\/JCI32878","article-title":"Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality","volume":"118","author":"Aljamali","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.031_bb0155","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI20106","article-title":"Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated factor VII","volume":"13","author":"Margaritis","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.031_bb0160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.thromres.2024.04.031_bb0165","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/rmv.1762","article-title":"Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them","volume":"23","author":"Hareendran","year":"2013","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.thromres.2024.04.031_bb0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.031_bb0175","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.thromres.2024.04.031_bb0180","doi-asserted-by":"crossref","first-page":"12267","DOI":"10.1002\/jcp.27972","article-title":"CRISPR\/Cas9 technology as a potent molecular tool for gene therapy","volume":"234","author":"Karimian","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.thromres.2024.04.031_bb0185","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.thromres.2024.04.031_bb0190","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtm.2020.06.025","article-title":"CRISPR-Cas9-mediated in vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice","volume":"18","author":"Wang","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.thromres.2024.04.031_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.785698","article-title":"Promoterless gene targeting approach combined to CRISPR\/Cas9 efficiently corrects hemophilia B phenotype in neonatal mice","volume":"4","author":"Lisjak","year":"2022","journal-title":"Front. Genome Ed."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0200","doi-asserted-by":"crossref","first-page":"16838","DOI":"10.1038\/s41598-019-53198-y","article-title":"Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0205","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1038\/s41598-017-04625-5","article-title":"CRISPR\/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice","volume":"7","author":"Ohmori","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2024.04.031_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.672564","article-title":"CRISPR\/Cas9-mediated in vivo genetic correction in a mouse model of hemophilia A","volume":"9","author":"Luo","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.031_bb0215","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12185-019-02765-0","article-title":"CRISPR\/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs","volume":"111","author":"Morishige","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.thromres.2024.04.031_bb0220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-142679","article-title":"Specific correction of the Intron-22 inverted factor VIII gene in autologous blood outgrowth endothelial cells from patients with severe hemophilia A","volume":"136","author":"Dinh","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0225","doi-asserted-by":"crossref","first-page":"10385","DOI":"10.1038\/s41598-018-28502-x","article-title":"Efficient targeted integration into the bovine Rosa26 locus using TALENs","volume":"8","author":"Wang","year":"2018","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.thromres.2024.04.031_bb0230","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1089\/hum.2019.164","article-title":"Rational engineering and preclinical evaluation of neddylation and SUMOylation site modified adeno-associated virus vectors in murine models of hemophilia B and leber congenital amaurosis","volume":"30","author":"Maurya","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.thromres.2024.04.031_bb0235","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1021\/acs.molpharmaceut.9b00959","article-title":"Molecular engineering of adeno-associated virus capsid improves its therapeutic gene transfer in murine models of hemophilia and retinal degeneration","volume":"16","author":"Mary","year":"2019","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.031_bb0240","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","article-title":"A coagulation factor IX-deficient mouse model for human hemophilia B","volume":"90","author":"Lin","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.031_bb0245","first-page":"jkac37","article-title":"Whole-genome sequencing identifies I-SceI-mediated transgene integration sites in Xenopus tropicalis snai2: eGFP line","volume":"12","author":"Wang","year":"2022","journal-title":"G3. Genes. Genomes. Genet."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.031_bb0250","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jth.13202","article-title":"Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene","volume":"14","author":"Chao","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.031_bb0255","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A hemophilia A mouse model for the in vivo assessment of emicizumab function","volume":"136","author":"Ferri\u00e8re","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0260","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jth.14644","article-title":"Enhanced potency of recombinant factor VIIa with increased affinity to activated platelets","volume":"18","author":"Enoksson","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.031_bb0265","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/jth.14243","article-title":"Factor XI promotes hemostasis in factor IX-deficient mice","volume":"16","author":"Mohammed","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.031_bb0270","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/hae.13428","article-title":"In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII","volume":"24","author":"Bar-Ilan","year":"2018","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2024.04.031_bb0275","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1111\/hae.12484","article-title":"A quantitative and humane tail bleeding assay for efficacy evaluation of antihaemophilic factors in haemophilia a mice","volume":"20","author":"Molina","year":"2014","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.thromres.2024.04.031_bb0280","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1093\/nar\/gkr068","article-title":"Detecting common copy number variants in high-throughput sequencing data by using JointSLM algorithm","volume":"39","author":"Magi","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.031_bb0285","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1093\/nar\/gks001","article-title":"Summarizing and correcting the GC content bias in high-throughput sequencing","volume":"40","author":"Benjamini","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"10.1016\/j.thromres.2024.04.031_bb0290","doi-asserted-by":"crossref","first-page":"W187","DOI":"10.1093\/nar\/gku365","article-title":"deepTools: a flexible platform for exploring deep-sequencing data","volume":"42","author":"Ram\u00edrez","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"6121","key":"10.1016\/j.thromres.2024.04.031_bb0295","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.thromres.2024.04.031_bb0300","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.omtn.2019.09.011","article-title":"Improved double-nicking strategies for COL7A1-editing by homologous recombination","volume":"18","author":"Kocher","year":"2019","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.thromres.2024.04.031_bb0305","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtn.2019.05.019","article-title":"ssODN-mediated in-frame deletion with CRISPR\/Cas9 restores FVIII function in hemophilia A-patient-derived iPSCs and ECs","volume":"17","author":"Hu","year":"2019","journal-title":"Mol. Ther. Nucleic Acids."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-022-03036-2","article-title":"Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR\/Cas9 technology","volume":"13","author":"Ma","year":"2022","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.031_bb0315","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/hum.2009.100","article-title":"Optimized adeno-associated virus (AAV)\u2013protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses","volume":"21","author":"Jayandharan","year":"2009","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.031_bb0320","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.ymthe.2018.02.023","article-title":"Efficient in vivo liver-directed gene editing using CRISPR\/Cas9","volume":"26","author":"Singh","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.thromres.2024.04.031_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12896-016-0234-4","article-title":"Efficient generation of Rosa26 knock-in mice using CRISPR\/Cas9 in C57BL\/6 zygotes","volume":"16","author":"Chu","year":"2016","journal-title":"BMC Biotechnol."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.031_bb0330","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1089\/hum.2017.016","article-title":"Gene delivery of activated factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies","volume":"28","author":"Sun","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.031_bb0335","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI20106","article-title":"Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated factor VII","volume":"113","author":"Margaritis","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.031_bb0340","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.V81.3.734.734","article-title":"Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation","volume":"81","author":"Morrissey","year":"1993","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.031_bb0345","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.V95.4.1330.004k28_1330_1335","article-title":"Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa","volume":"95","author":"van\u2019t Veer","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.031_bb0350","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2516.2010.02460.x","article-title":"Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX","volume":"17","author":"Valentino","year":"2011","journal-title":"Haemophilia"},{"issue":"13","key":"10.1016\/j.thromres.2024.04.031_bb0355","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1182\/blood-2009-03-212423","article-title":"Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice","volume":"114","author":"Pan","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2024.04.031_bb0360","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/jth.13766","article-title":"Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein","volume":"15","author":"Ay","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0365","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/mt.2013.197","article-title":"Platelet Gene Therapy by Lentiviral Gene Delivery to Hematopoietic Stem Cells Restores Hemostasis and Induces Humoral Immune Tolerance in FIXnull mice","volume":"22","author":"Chen","year":"2014","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0370","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1038\/s41467-022-34898-y","article-title":"Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response","volume":"13","author":"He","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.thromres.2024.04.031_bb0375","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.omtm.2021.04.011","article-title":"Targeting the Apoa1 locus for liver-directed gene therapy","volume":"21","author":"De Giorgi","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"26","key":"10.1016\/j.thromres.2024.04.031_bb0380","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.2019000790","article-title":"CRISPR\/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX\u2013knockout mice","volume":"133","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2024.04.031_bb0385","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41591-018-0184-6","article-title":"In utero CRISPR-mediated therapeutic editing of metabolic genes","volume":"24","author":"Rossidis","year":"2018","journal-title":"Nat. Med."},{"issue":"25","key":"10.1016\/j.thromres.2024.04.031_bb0390","doi-asserted-by":"crossref","first-page":"9253","DOI":"10.1073\/pnas.1323941111","article-title":"Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs","volume":"111","author":"Park","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0395","doi-asserted-by":"crossref","first-page":"18865","DOI":"10.1038\/srep18865","article-title":"In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.031_bb0400","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/bloodadvances.2016001651","article-title":"Accurate, simple, and inexpensive assays to diagnose F8 gene inversion mutations in hemophilia A patients and carriers","volume":"1","author":"Dutta","year":"2016","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2024.04.031_bb0405","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-engineered coagulation factors for hemophilia gene therapy","volume":"12","author":"Samelson-Jones","year":"2019","journal-title":"Mol. Ther. Methods. Clin. Dev."},{"key":"10.1016\/j.thromres.2024.04.031_bb0410","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04766","article-title":"Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery","volume":"3","author":"Lin","year":"2014","journal-title":"elife"},{"key":"10.1016\/j.thromres.2024.04.031_bb0415","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.omtn.2019.02.009","article-title":"The chromatin structure of CRISPR-Cas9 target DNA controls the balance between mutagenic and homology-directed gene-editing events","volume":"16","author":"Janssen","year":"2019","journal-title":"Mol. Ther. Nucleic Acids."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.031_bb0420","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/nat.2015.0545","article-title":"Combining CRISPR\/Cas9 and rAAV templates for efficient gene editing","volume":"25","author":"Kaulich","year":"2015","journal-title":"Nucleic Acids Ther."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.031_bb0425","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/stem.2935","article-title":"Improving gene editing outcomes in human hematopoietic stem and progenitor cells by temporal control of DNA repair","volume":"37","author":"Lomova","year":"2019","journal-title":"Stem Cells"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.031_bb0430","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molcel.2016.07.004","article-title":"Methods for optimizing CRISPR-Cas9 genome editing specificity","volume":"63","author":"Tycko","year":"2016","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.031_bb0435","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nbt.2808","article-title":"Improving CRISPR-Cas nuclease specificity using truncated guide RNAs","volume":"32","author":"Fu","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.031_bb0440","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0445","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2516.2006.01403.x","article-title":"Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors","volume":"13","author":"Astermark","year":"2007","journal-title":"Haemophilia"},{"issue":"07","key":"10.1016\/j.thromres.2024.04.031_bb0450","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0033-1356574","article-title":"Challenges in the management of hemophilia B with inhibitor","volume":"39","author":"Batorova","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"issue":"06","key":"10.1016\/j.thromres.2024.04.031_bb0455","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/s-0038-1660817","article-title":"Inhibitors in hemophilia B","volume":"44","author":"Santoro","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2024.04.031_bb0460","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115153","article-title":"Thrombotic events with NovoSeven\u00ae RT in approved indications are rare (0.2%) and associated with older age (\u2265 65 y), cardiovascular disease, and concomitant use of aPCCs","volume":"132","author":"Rajpurkar","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2024.04.031_bb0465","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1538-7836.2004.00944.x","article-title":"Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity","volume":"2","author":"Aledort","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"15","key":"10.1016\/j.thromres.2024.04.031_bb0470","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2010-09-309732","article-title":"Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo","volume":"117","author":"Margaritis","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.031_bb0475","first-page":"87","article-title":"Anticlotting mechanisms 1: physiology and pathology","volume":"13","author":"Ezihe-Ejiofor","year":"2013","journal-title":"BJA Educ."},{"key":"10.1016\/j.thromres.2024.04.031_bb0480","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.omtn.2022.08.002","article-title":"Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia","volume":"29","author":"Lee","year":"2022","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.thromres.2024.04.031_bb0485","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.thromres.2024.04.031_bb0490","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1039\/D1BM01452H","article-title":"Pre-clinical non-viral vectors exploited for in vivo CRISPR\/Cas9 gene editing: an overview","volume":"10","author":"Rouatbi","year":"2022","journal-title":"Biomater. Sci."},{"issue":"11","key":"10.1016\/j.thromres.2024.04.031_bb0495","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.031_bb0500","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1038\/ncomms7952","article-title":"Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium","volume":"6","author":"McNeer","year":"2015","journal-title":"Nat. Commun."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T08:40:48Z","timestamp":1716021648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":100,"alternative-id":["S0049384824001506"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.031","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}